GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Solasia Pharma KK (STU:9SO) » Definitions » EV-to-FCF

Solasia Pharma KK (STU:9SO) EV-to-FCF : -15.10 (As of Mar. 30, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Solasia Pharma KK EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Solasia Pharma KK's Enterprise Value is €45.56 Mil. Solasia Pharma KK's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-3.02 Mil. Therefore, Solasia Pharma KK's EV-to-FCF for today is -15.10.

The historical rank and industry rank for Solasia Pharma KK's EV-to-FCF or its related term are showing as below:

STU:9SO' s EV-to-FCF Range Over the Past 10 Years
Min: -45.9   Med: -6.08   Max: -2.83
Current: -14.76

During the past 12 years, the highest EV-to-FCF of Solasia Pharma KK was -2.83. The lowest was -45.90. And the median was -6.08.

STU:9SO's EV-to-FCF is ranked worse than
100% of 549 companies
in the Drug Manufacturers industry
Industry Median: 23.45 vs STU:9SO: -14.76

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-30), Solasia Pharma KK's stock price is €0.222. Solasia Pharma KK's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.045. Therefore, Solasia Pharma KK's PE Ratio (TTM) for today is At Loss.


Solasia Pharma KK EV-to-FCF Historical Data

The historical data trend for Solasia Pharma KK's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solasia Pharma KK EV-to-FCF Chart

Solasia Pharma KK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.16 -5.18 -3.01 -19.94 -6.76

Solasia Pharma KK Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.61 -19.94 -6.78 -10.12 -6.76

Competitive Comparison of Solasia Pharma KK's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Solasia Pharma KK's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solasia Pharma KK's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Solasia Pharma KK's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Solasia Pharma KK's EV-to-FCF falls into.


;
;

Solasia Pharma KK EV-to-FCF Calculation

Solasia Pharma KK's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=45.564/-3.018
=-15.10

Solasia Pharma KK's current Enterprise Value is €45.56 Mil.
Solasia Pharma KK's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Solasia Pharma KK  (STU:9SO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Solasia Pharma KK's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.222/-0.045
=At Loss

Solasia Pharma KK's share price for today is €0.222.
Solasia Pharma KK's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.045.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Solasia Pharma KK EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Solasia Pharma KK's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Solasia Pharma KK Business Description

Traded in Other Exchanges
Address
2-1-1 Shiba Park, 4th Floor, Sumitomo Real Estate Shiba Park Tower, Minato-ku, Tokyo, JPN, 105-0011
Solasia Pharma KK develops and distributes pharmaceuticals and medical devices relating to malignant tumors.

Solasia Pharma KK Headlines

No Headlines